Arrowhead completes enrollment of first cohort in phase 2a trial of ARC-520 Arrowhead Research Corporation announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter. The Phase 2a study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen decline, among other measures, in response to a single dose of ARC-520.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.